Metacrine Demonstrates Best-in-Class FXR Drug Program with Positive Clinical Results in NASH Patients
Randomized, placebo-controlled 12-week study showed mean liver fat reduction of up to 55% with MET409 93% of patients showed liver fat reduction of at least 30% from baseline SAN DIEGO, January 22, 2020 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI)… Read More
Metacrine to Present at Jefferies 2019 London Healthcare Conference
SAN DIEGO, November 18, 2019 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, today announced that Ken Song, M.D., President and CEO, will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20, 2019 at 7:40 a.m. ET… Read More
Metacrine to Present at H.C. Wainwright 2019 NASH Investor Conference
SAN DIEGO, October 15, 2019 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, today announced that Hubert Chen, M.D., Chief Medical Officer, will present at the H.C. Wainwright 2019 NASH Investor Conference on Monday, October 21, 2019 at 2:20 p.m. EDT… Read More
Metacrine Secures $50 Million Growth Capital Facility from K2 HealthVentures
SAN DIEGO, September 18, 2019 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, today announced it has entered into a loan and security agreement for up to $50 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company. “This financing bolsters… Read More
Metacrine Doses First Patient in 12-Week NASH Proof-of-Concept Trial with a Sustained FXR Agonist
Placebo-controlled, multi-center trial will evaluate safety, tolerability and efficacy biomarkers to assess potential best-in-class FXR agonist SAN DIEGO, July 9, 2019 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, today announced that the first patient has been dosed in its 12-week,… Read More
Metacrine to Present Initial Clinical NASH Data with Sustained FXR Agonist at Paris NASH Meeting 2019
Promising signs of clinical efficacy without increase in LDL cholesterol SAN DIEGO, July 2, 2019 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, will present initial clinical data in nonalcoholic steatohepatitis (NASH) patients with MET409, a sustained non-bile acid FXR agonist.… Read More
Metacrine Reports Positive Interim Results with Sustained FXR Agonist in NASH Patients
MET409, a non-bile acid sustained FXR agonist, showed no change in LDL cholesterol, no pruritis and favorable trends in liver fat reduction SAN DIEGO, May 29, 2019 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, today announced interim results from its… Read More
Metacrine to Present at Jefferies 2019 Global Healthcare Conference
SAN DIEGO, May 21, 2019 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, today announced that Ken Song, M.D., President and CEO, will present at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019 at 4:00 p.m. EDT (1:00… Read More
Metacrine to Present Relevance of FXR and Specific FXR Drug Profiles for Possible Treatment of Inflammatory Bowel Disease at Digestive Disease Week 2019
SAN DIEGO, May 13, 2019 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, will present data showing efficacy of M480, a potent oral non-bile acid farnesoid X receptor (FXR) agonist, in multiple models of inflammatory bowel disease (IBD). FXR activation… Read More
Metacrine to Present Phase 1 Results of MET409, an Optimized Next Generation FXR Agonist at The International Liver Congress (EASL) 2019
SAN DIEGO, April 3, 2019 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, will present data showing MET409, a potent, systemic and sustained non-bile acid farnesoid X receptor (FXR) agonist, is safe and well tolerated in a Phase 1 study of… Read More
Metacrine to Present Rapid Efficacy of MET409 in a NASH Mouse Model at The Liver Meeting 2018
SAN DIEGO, November 5, 2018 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, will present data showing rapid efficacy of MET409, a potent, systemic and sustained non-bile acid farnesoid X receptor (FXR) agonist in a biopsy confirmed nonalcoholic steatohepatitis (NASH)… Read More
Metacrine Appoints Hubert Chen, M.D. as Chief Medical Officer and Andrew Guggenhime to the Board of Directors
SAN DIEGO, September 6, 2018 – Metacrine, Inc., a biotechnology company developing therapies to benefit patients with liver and gastrointestinal diseases (GI), today announced the appointment of Hubert C. Chen, M.D., as Chief Medical Officer, and Andrew Guggenhime as a director of the company. Dr. Chen most recently served as Chief Medical and Scientific Officer… Read More
Metacrine Completes Dosing of First Cohort in Phase 1 Trial of MET409, a Novel Non-Bile Acid FXR Agonist
San Diego, CA – Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced dosing of the first subjects in a Phase 1 randomized, double-blind, placebo-controlled, safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) trial of its lead product candidate MET409. The trial is a single and… Read More
Metacrine Completes $65 Million Series C Financing
Proceeds will support clinical development of FXR program in NASH and GI diseases San Diego, CA – Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced it has completed a Series C financing which raised $65 million in new funds. The investment was led by… Read More
Metacrine to Present at Jefferies 2018 Global Healthcare Conference
San Diego, CA – Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced that Ken Song, M.D., President and CEO, will present at the Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018 at 3:30 p.m. EDT (12:30 p.m. PDT) in New York City.… Read More
Metacrine to Present Role of FXR in Treating Inflammatory Bowel Disease at Digestive Disease Week 2018
San Diego, CA – Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today presented data showing equivalent efficacy of M480, a potent oral non-bile acid farnesoid X receptor (FXR) agonist for the potential treatment of inflammatory bowel disease (IBD), to anti-IL-12/23, a biologic agent. The oral… Read More
Metacrine Broadens Management Team with Two Key Hires
San Diego, CA – Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced two new key management appointments. Trisha M. Millican has joined the company as Chief Financial Officer, while Karl F. Cremer, Pharm.D., has been appointed Vice President, Clinical Operations. “I am delighted to… Read More
Metacrine to Present Two Abstracts on its Novel FXR Non-Bile Acid Agonist Program at the EASL International Liver Congress 2017
San Diego, CA – Metacrine, Inc., a leading and innovative biotechnology company focused on drug development for metabolic diseases, announced it will present two abstracts on its novel FXR agonist program at the upcoming International Liver Congress Meeting of the European Association for the Study of Liver Disease (EASL) in Amsterdam, Netherlands. Metacrine has developed… Read More
Metacrine to Present at 30th Annual ROTH Conference
Corporate and panel presentations as part of NASH program San Diego, CA – Metacrine, Inc., an innovative biotechnology company focused on drug development, today announced that Ken Song, MD, President and CEO, will give a corporate presentation and participate in a NASH panel discussion at the 30th Annual ROTH Conference taking place at the Ritz-Carlton… Read More
Metacrine Completes Series B Financing to Advance Best-in-Class FXR Program into Clinical Development
San Diego, CA – Metacrine, Inc., an innovative biotechnology company focused on drug development, today announced it has closed a $22M Series B financing led by new investor New Enterprise Associates (NEA), along with participation from existing investors ARCH, Polaris, venBio, and Alexandria Venture Investments. As part of the new financing, Carol Gallagher, Pharm D,… Read More
Metacrine’s FXR Program to be Highlighted in Three Abstracts at The Liver Meeting® 2017 in Washington, D.C.
San Diego, CA – Metacrine, Inc., an innovative biotechnology company focused on drug development for metabolic diseases, announced it will present three abstracts on its novel FXR agonist program at the upcoming American Academy for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®) in Washington, D.C. Metacrine has developed an industry leading… Read More
Metacrine Announces Appointment of Dr. Ken Song as President and Chief Executive Officer
San Diego, CA – Metacrine, Inc., a biotechnology company focused on developing innovative therapeutics in metabolic disease through advances in endocrine research, today announced the appointment of Ken Song, M.D., as its new president, chief executive officer and director. Dr. Song was most recently co-founder and chief executive officer of Ariosa Diagnostics, which was acquired… Read More
Metacrine Raises $36 Million in Series A Financing
Appoints Neil McDonnell, CEO, Along with Executive Team and Board San Diego, CA – Metacrine, Inc., a biotechnology company focused on targeting metabolic disease through advances in endocrine research, today announced it has raised $36 million in a Series A financing. The financing included participation from Arch Venture Partners, EcoR1 Capital, Polaris Partners and venBio.… Read More